Monographie - Ceftobiprole medocaril sodium

Ostatnia aktualizacja :
16/12/2025

Ceftobiprole medocaril sodium

Struktura chemiczna

Nazwa handlowa

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Adaluzis	Irlandia
Mabelio	Francja
Zevtera	Finlandia, Hiszpania, Meksyk, Niemcy, Norwegia, Peru, Szwajcaria, Szwecja, Wielka Brytania

Bibliografia : Ceftobiprole medocaril sodium

	typ	publikacja
2269	Czasopismo	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3520	Laboratorium	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Laboratorium	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laboratorium	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratorium	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
4650	Laboratorium	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
5098	Czasopismo	Esteban‑Cartelle B, Anaya B.J, Menéndez‑Conde C.P, Vicente‑Oliveros N , Serrano D.R, Álvarez‑Díaz A. Stability of Ceftobiprole Medocaril in Portable Elastomeric Infusion Devices. Infect Dis Ther 2025 ; 14:1685–1696.

Mentions Légales